Inspire Investing’s ImmunityBio IBRX Stock Holding History

Inspire Investing’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-63	Closed	–	–	602
2020 Q1	$0	Buy	+63	New	+$316	﹤0.01%	764
2018 Q1	–	Sell	-250	Closed	-$1K	–	428
2017 Q4	$1K	Buy	+250	New	+$1.18K	﹤0.01%	866

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Inspire Investing's IBRX Position: Q2 2020 in Review

Inspire Investing sold out of ImmunityBio (IBRX) in Q2 2020, closing a stake of 63 shares.

Inspire Investing first reported a position in IBRX in Q4 2017 and held it in 2 quarters. The position peaked at $1K in Q4 2017. 85 funds tracked by Wall St. Rank hold IBRX as of Q2 2020.

Inspire Investing reported no remaining ImmunityBio position as of Q2 2020 after selling out during the quarter.
Inspire Investing sold 63 ImmunityBio shares in Q2 2020.
Inspire Investing first reported a position in ImmunityBio in Q4 2017 and held it in 2 quarters.
Inspire Investing's ImmunityBio position peaked at $1K in Q4 2017.
85 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2020.

Based on Inspire Investing's 13F filing for Q2 2020, filed 12 Aug 2020.